title: NF-κB as potential target in the treatment of melanoma.
abstract: The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents. Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.
authors.affiliation: Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione, G, Pascale, Napoli, Italy.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Madonna
authors.forename: Claudio Dansky
authors.initials: CD
authors.lastname: Ullman
authors.forename: Giusy
authors.initials: G
authors.lastname: Gentilcore
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Palmieri
authors.forename: Paolo Antonio
authors.initials: PA
authors.lastname: Ascierto
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000378:metabolism* / Q000628:therapy*; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D016328:NF-kappa B